All In Biotech

Drug Trial Radar · NCT04108208

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase IV Study of Apalutamide in Chinese Participants With Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC)

Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

75

Actual

Start

Dec 17, 2019

Primary completion

Jun 1, 2023

Study completion Jun 5, 2026

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Sep 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 \[PCWG2\]) of apalutamide versus placebo in Chinese participants with high-risk non-metastatic castration resistant prostate cancer (NM-CRPC).

Conditions

  • Prostatic Neoplasms

Interventions

  • ApalutamideDrug

    Apalutamide 240 mg (4\*60 mg tablets) will be administrated orally once daily.

  • PlaceboDrug

    Matching placebo will be administered orally.

  • Androgen-deprivation Therapy (ADT)Drug

    Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Prostate Specific Antigen (PSA) Progression (TTPP) Based on Prostate Cancer Working Group 2 (PCWG2) CriteriaTime frame: From randomization until first documented PSA progression (up to 3 years 3 months)

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China

  • Peking University First Hospital

    Beijing, China

  • Peking University People's Hospital

    Beijing, China

  • Beijing Friendship Hospital

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • Beijing Hospital

    Beijing, China

  • Hunan Cancer hospital

    Changsha, China

  • Sichuan Provincial Peoples Hospital

    Chengdu, China

  • Chongqing University Cancer Hospital

    Chongqing, China

  • Fujian Medical University Union Hospital

    Fuzhou, China

  • Sun Yat-Sen Memorial Hospital Sun Yat-sen University

    Guangzhou, China

  • Guangzhou First Municipal People's Hospital

    Guangzhou, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, China

  • The First Affiliated Hospital Zhejiang University College of Medicine

    Hangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Nanjing Drum Tower Hospital

    Nanjing, China

  • The First Affiliated Hospital of Ningbo University

    Ningbo, China

  • Cancer Hospital, FuDan University

    Shanghai, China

  • Shanghai Zhongshan Hospital

    Shanghai, China

  • Huashan Hospital Fudan University

    Shanghai, China

  • Renji Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China

  • The Fifth People's Hospital of Shanghai, Fudan University

    Shanghai, China

  • Huadong Hospital Affiliated to Fudan University

    Shanghai, China

  • First Affiliated Hospital SooChow University

    Suzhou, China

  • TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology

    Wuhan, China

  • Wuxi People s Hospital

    Wuxi, China

  • The First Affiliated Hospital of Xian Jiaotong University

    Xi'an, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.